Continued Suppression of Serum TSH Level May Be Attributed to TSH Receptor Antibody Activity As Well As the Severity of Thyrotoxicosis and the Time to Recovery of Thyroid Hormone in Treated Euthyroid Graves' Patients

Thyroid ◽  
2006 ◽  
Vol 16 (12) ◽  
pp. 1251-1257 ◽  
Author(s):  
Yun Jae Chung ◽  
Byung Wan Lee ◽  
Ji-Youn Kim ◽  
Jung Hwa Jung ◽  
Yong-Ki Min ◽  
...  
Keyword(s):  
Thyroid Hormone ◽  
Tsh Receptor ◽  
Antibody Activity ◽  
Receptor Antibody ◽  
Tsh Receptor Antibody ◽  
Serum Tsh

scholarly journals Determinants of Extraocular Muscle Volume in Patients with Graves' Disease

2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
Samer El-Kaissi ◽  
Jack R. Wall
Keyword(s):  
Extraocular Muscle ◽  
Tsh Receptor ◽  
Graves Disease ◽  
Thyroid Function Tests ◽  
Thyroid Scintigraphy ◽  
Free T4 ◽  
Receptor Antibody ◽  
Tsh Receptor Antibody ◽  
Antibody Positivity ◽  
Serum Tsh

Background. To examine factors contributing to extraocular muscle (EOM) volume enlargement in patients with Graves’ hyperthyroidism.Methods. EOM volumes were measured with orbital magnetic resonance imaging (MRI) in 39 patients with recently diagnosed Graves’ disease, and compared to EOM volumes of 13 normal volunteers. Thyroid function tests, uptake on thyroid scintigraphy, anti-TSH-receptor antibody positivity and other parameters were then evaluated in patients with EOM enlargement.Results. 31/39 patients had one or more enlarged EOM, of whom only 2 patients had clinical EOM dysfunction. Compared to Graves’ disease patients with normal EOM volumes, those with EOM enlargement had significantly higher mean serum TSH (0.020±0.005versus0.007±0.002mIU/L;Pvalue 0.012), free-T4 (52.9±3.3versus41.2±1.7 pmol/L;Pvalue 0.003) and technetium uptake on thyroid scintigraphy (13.51±1.7%versus8.55±1.6%;Pvalue 0.045). There were no differences between the 2 groups in anti-TSH-receptor antibody positivity, the proportion of males, tobacco smokers, or those with active ophthalmopathy.Conclusions. Patients with recently diagnosed Graves’ disease and EOM volume enlargement have higher serum TSH and more severe hyperthyroidism than patients with normal EOM volumes, with no difference in anti-TSH-receptor antibody positivity between the two groups.

scholarly journals Kinetic analyses of changes in serum TSH receptor antibody values after total thyroidectomy in patients with Graves’ disease

2016 ◽  
Vol 63 (2) ◽  
pp. 179-185 ◽  
Author(s):  
Waka Yoshioka ◽  
Akira Miyauchi ◽  
Mitsuru Ito ◽  
Takumi Kudo ◽  
Hidekazu Tamai ◽  
...  
Keyword(s):  
Total Thyroidectomy ◽  
Tsh Receptor ◽  
Receptor Antibody ◽  
Tsh Receptor Antibody ◽  
Serum Tsh

scholarly journals Changes in Serum TSH Receptor Antibody (TRAb) Values in Patients with Graves' Disease after Total or Subtotal Thyroidectomy

2003 ◽  
Vol 50 (5) ◽  
pp. 595-601 ◽  
Author(s):  
Yuuki TAKAMURA ◽  
Keiichi NAKANO ◽  
Takashi URUNO ◽  
Yasuhiro ITO ◽  
Akihiro MIYA ◽  
...  
Keyword(s):  
Subtotal Thyroidectomy ◽  
Tsh Receptor ◽  
Graves Disease ◽  
Receptor Antibody ◽  
Tsh Receptor Antibody ◽  
Serum Tsh

Precise Determination of TSH Receptor Antibody Activity in Serum Containing Bovine TSH (bTSH) Binding Antibody by Absorption Using Denatured bTSH or Sheep FSH

Thyroid ◽  
1996 ◽  
Vol 6 (4) ◽  
pp. 295-299 ◽  
Author(s):  
TAKEHIRO INUI ◽  
TSUYOSHI KOUKI ◽  
HIDETOSHI OKABE ◽  
YUKIO OCHI ◽  
TAKASHI HACHIYA ◽  
...  
Keyword(s):  
Precise Determination ◽  
Tsh Receptor ◽  
Antibody Activity ◽  
Receptor Antibody ◽  
Tsh Receptor Antibody ◽  
Binding Antibody ◽  
Bovine Tsh

scholarly journals Long-Term Antithyroid Drug Treatment: Trends in Serum TSH and TSH Receptor Antibody Changes in Patients with Graves’ Disease

2020 ◽  
Vol 18 (Suppl) ◽  
Author(s):  
Ken Okamura ◽  
Sachiko Bandai ◽  
Megumi Fujikawa ◽  
Kaori Sato ◽  
Hiroshi Ikenoue ◽  
...  
Keyword(s):  
Drug Treatment ◽  
Antithyroid Drug ◽  
Tsh Receptor ◽  
Free T4 ◽  
Receptor Antibody ◽  
Tsh Receptor Antibody ◽  
Antithyroid Drug Treatment ◽  
Long Term Prognosis ◽  
Serum Tsh

Objectives: Trends in serum thyroid-stimulating hormone (TSH) and TSH receptor antibody (TRAb) changes during antithyroid drug treatment, and long-term prognosis were evaluated in Graves’ hyperthyroidism (GD). Methods: In 609 GD patients initially treated with 15 mg of methyl-mercapto imidazole (MMI), the changes in serum TRAb and long-term prognosis were compared in the TSH-normalized group (A) and the TSH-suppressed group (B and C) during the initial 180 days of treatment. Results: Early responses to MMI during 180 days of treatment were as follows: 48 cases (7.9%) became hypothyroid with elevated TSH (A1), and 188 cases (30.9%) became euthyroid with normal TSH (A2). Among patients with continuously suppressed TSH, the free T4 (fT4) level was low in 31 cases (5.1%) (B1-inappropriately suppressed TSH), fT4 and fT3 were normal in 185 cases (30.4%) (B2), fT4 was normal, but fT3 remained high in 84 cases (13.8%) (B3), and fT4 remained high in 73 cases (12.0%) (C-refractory). Serum TRAb became negative after < 5 years then remained negative in 25% - 51% of the cases (smooth type), became negative after < 5 years then became positive again in 30% - 43% of the cases (fluctuating type), and remained positive after > 5 years in 10% - 42% of the cases (smoldering type). In total, remission occurred after 6.2 (3.0 - 10.4) years of treatment in 42%, possible remission on a small maintenance dosage of antithyroid drug occurred in 13%, and spontaneous hypothyroidism occurred in 4.4% of the cases. The smoldering type was more frequent in the B1 and C groups than in others, and remission was less frequent. The difference in the long-term prognosis depending on the early response to MMI disappeared after excluding the ablated patients. Without ablation, remission or spontaneous hypothyroidism could be expected in 60% - 75% of patients after tenacious treatment for > 10 years. Conclusions: Prolonged suppression of serum TSH may suggest active TRAb activity during treatment, and continuous TRAb positivity for more than 5 years suggests persistent GD activity.

scholarly journals Changes in TSH-Receptor Antibody (TR-AB) and Thyroid Stimulating Antibody (TS-AB) after Thyroidectomy in Thyrotoxic Patients

1990 ◽  
Vol 66 (8) ◽  
pp. 727-736 ◽  
Author(s):  
Hiroyuki HOSOJIMA ◽  
Eiji MIYAUCHI ◽  
Hiroshi OKADA ◽  
Sadahide AZUKIZAWA ◽  
Ikuo YAMAMOTO ◽  
...  
Keyword(s):  
Tsh Receptor ◽  
Receptor Antibody ◽  
Thyroid Stimulating Antibody ◽  
Tsh Receptor Antibody

TSH receptor antibody-associated thyroid dysfunction following subacute thyroiditis

1998 ◽  
Vol 48 (4) ◽  
pp. 445-453 ◽  
Author(s):  
Makoto Iitaka ◽  
Naoko Momotani ◽  
Toshihiko Hisaoka ◽  
Jaeduk Yoshimura Noh ◽  
Naofumi Ishikawa ◽  
...  
Keyword(s):  
Thyroid Dysfunction ◽  
Subacute Thyroiditis ◽  
Tsh Receptor ◽  
Receptor Antibody ◽  
Tsh Receptor Antibody
Sign in / Sign up

Export Citation Format

Share Document